Raghu Rao has served on Sonnet’s board of directors since November 2019. Mr. Rao is a serial entrepreneur, strategic business advisor and angel investor. Mr. Rao has founded, scaled and had successful exits with several high-technology companies. In his 33-year career, Mr. Rao has advised clients on the strategy and roll-out of high-profile projects, such as USA.gov, TSA Screening Gateway, Cancer.gov and other eGovernment initiatives. As the Vistage Princeton Chair, from July 2012 to March 2017, Mr. Rao ran three high-performing peer advisory boards for middle-market CEOs and business leaders of companies with total revenues exceeding $2 Billion. As the Chairman & President of InfoZen from August 1995 to July 2008, Mr. Rao has managed over $1 Billion in U.S. Federal Government contracts. Mr. Rao is a 20-year Charter Member of The Indus Entrepreneurs (TiE.org) and a 5-year patron of the Indiaspora. He has held board positions at several companies including Cellix BioSciences (Jan 2016 - Jan 2017), Paper Battery Company (Jan 2009 - Dec 2018), Kovid Group (Feb 2016 - Oct 2017) , WizNucleus (Jun 2010 - present) and InfoZen (Aug 1995 - Jul 2008). Mr. Rao is active in social entrepreneurship and community service. He co-founded the Hindu Jewish Coalition in December 2012 and Forum for Religious Freedom in March 2007 to preserve religious diversity worldwide. He has held non-profit board positions at the Infinity Foundation (New Jersey), Arsha Vidya Gurukulam (Pennsylvania) and the Family Services Agency (Maryland). Mr. Rao has an MBA in Finance from George Washington University (Dec 1991), an M.S. in Computer Science from Virginia Tech (Dec 1986), and a B.Tech. in Electrical Engineering from Indian Institute of Technology, Madras (June 1984).

Donald Griffith has over 30 years of experience in finance and accounting and has held several CFO and financial leadership positions with 22 years in public accounting and more than 10 years in corporate finance. He has served as Sonnet's Chief Financial Officer since February 2025. Prior to that, he was the Financial Controller for Sonnet begining in January 2019. Mr. Griffith also sits on the Board of Directors of Sonnet and was Chairman of the Company from April 2015 to June 2018.  Earlier, Mr. Griffith was the Chief Financial Officer, Director and Secretary of Oncobiologics Inc. (Now Outlook Therapeutics Nasdaq: OTLK) from 2011 to 2018. Mr. Griffith has over 40 years’ experience in finance and accounting and is the founder and Partner of Stolz & Griffith, LLC, a New Jersey accounting firm. He holds a business degree from City College of New York and an MBA from Fairleigh Dickinson University and is a member of the American Institute of Certified Public Accountants and the New Jersey Society of CPAs.

Dr. John Cini is Chief Scientific Officer and a Co-Founder of Sonnet BioTherapeutics, where he oversees and directs the company’s discovery and development programs. His role includes the oversight of the selection process of cancer and immune-oncology targets and proof-of-concept testing.

Prior to joining Sonnet, he was Vice President of Discovery and Development Sciences at Oncobiologics. He has successfully advanced more than 20 novel monoclonal antibody products from discovery to IND. He is the holder of several novel product and formulation patents and applications. He has been directly involved in several successful novel biologics through early discovery research into development and manufacturing through clinical trials and commercialization.

Previous positions include Executive Director at Mederex (acquired by Bristol-Myers Squibb in 2010), lead discovery scientific roles at Johnson & Johnson (Ethicon, OrthoBioTech & Pharmaceutical Research), and Bayer. Dr. Cini’s therapeutic areas of expertise in system biology including -oncology, immune-oncology, inflammation, osteoporosis, wound healing, surgical adhesion, and cellular aging.

Susan Dexter serves as Sonnet’s Chief Technical Officer. She comes to Sonnet with more than twenty-five years in biotechnology science, manufacturing and business development. Susan’s experience includes management of biotechnology contract manufacturing services ranging from process development through commercial manufacturing, and strategic consulting related services. Her prior roles include Managing Director, Latham Biopharm Group; Chief Business Officer at Xcellerex, Inc.; VP of Business Development at The Dow Chemical Company; Assoc. Director of Business Development, Celltech and Lonza.

Ms. Dexter holds a double major with Honors in Immunology and Marketing from American University, Washington, D.C.

Dr. Kenney has more than 20 years of experience in translational-stage development of biologics, as well as the commercialization strategy and corporate management of preclinical, clinical-stage and commercialized vaccines and immunotherapies. As President of ClinReg Biologics, he has provided strategic consulting in clinical and regulatory affairs of biologics, medical monitoring and pharmacovigilance in several capacities. Dr. Kenney most recently served as Chief Development Officer at X-VAX Technology and previously held Chief Medical Officer roles at Immune Design and Crucell Holland, where he led the clinical development and regulatory affairs groups. Dr. Kenney was a researcher/reviewer for the FDA for over six years and did post-graduate training at Duke and NIH. Dr. Kenney received a B.S. in Chemistry from George Washington University and his M.D. from Harvard Medical School.

Dr. Stephen J. McAndrew joined Sonnet BioTherapeutics in February, 2020 and currently serves as Chief Business Officer.  Prior to joining Sonnet, from March 2014 to October 2019, Dr. McAndrew served as the Senior Vice President of Business Strategy & Development and from February 2012 to March 2014, served as the Vice President of Business Development at Oncobiologics, Inc..  From December 2009 to March 2011, Dr. McAndrew served as the Vice President of Scientific Commercial Development at Taconic Biosciences, Inc., a contract research and biotechnology company, and from August 2007 to December 2009, Dr. McAndrew served as the Vice President of Business Development at Caliper Life Sciences, Inc., a biotechnology company, and prior to that, from January 2004 to August 2007, Dr. McAndrew served as Vice President of Business Development at Xenogen Biosciences Corporation, a provider of in vivo drug discovery services.  From January 2001 to December 2003, Dr. McAndrew served as the Vice President of Pharmaceutical Business Development at Lexicon Pharmaceuticals, Inc., a biopharmaceutical drug discovery and development company.  Prior to that, from March 1993 to December 2001, Dr. McAndrew served in various positions of increasing responsibility at Bristol-Myers Squibb Company, including as the Director of Biotechnology Licensing within the External Science and Technology (“EST”) Department.

Dr. McAndrew earned his Ph.D. in Molecular and Cellular Biology from Ohio University, an M.S in Molecular Genetics from the State University of New York at Albany and a B.S from the State University of New York at Oswego, and since completing his formal education, has directed exploratory research programs while at Hoffmann-La Roche in Nutley, New Jersey from 1980 to 1986 and then went on to direct specific research programs while in Oncology Drug Discovery at Bristol-Myers Squibb in the early to mid-90’s.